|
Randomized Controlled Trial of a Dichoptic Digital Therapeutic for Amblyopia.
PMID 34534556 · Ophthalmology · 2022-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
PMID 34529963 · Lancet Infect Dis · 2022-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.
PMID 34529962 · Lancet Infect Dis · 2022-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.
PMID 34514692 · Diabetes Obes Metab · 2022-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.
PMID 34514682 · Diabetes Obes Metab · 2022-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Japanese cedar pollen sublingual immunotherapy is effective in treating seasonal allergic rhinitis during the pollen dispersal period for Japanese cedar and Japanese cypress.
PMID 34509370 · Allergol Int · 2022-Jan
记录类型属于综述、Meta 分析、社论、评论、病例或指南。
|
H
L
|
旧查询独有 |
excludedexcluded_publication_type |
pending
0 Figure · 0 Panel · risk -
|
|
Preoperative systemic chemotherapy alters the histopathological growth patterns of colorectal liver metastases.
PMID 34480530 · J Pathol Clin Res · 2022-Jan
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
B
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial.
PMID 34468869 · Gastric Cancer · 2022-Jan
原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
|
H
L
B
|
旧查询独有 |
eligiblephase3_publication_type |
confirmed
3 Figure · 8 Panel · risk visible
|
|
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial.
PMID 34416294 · J Am Acad Dermatol · 2022-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.
PMID 34343599 · J Am Acad Dermatol · 2022-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma.
PMID 34304248 · Leukemia · 2022-Jan
原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
|
H
L
B
|
旧查询独有 |
eligiblephase3_publication_type |
needs_review
1 Figure · 2 Panel · risk unclear
|
|
Effect of Residual Retinal Fluid on Visual Function in Ranibizumab-Treated Neovascular Age-Related Macular Degeneration.
PMID 34289338 · Am J Ophthalmol · 2022-Jan
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial.
PMID 34289086 · Br J Dermatol · 2022-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Assessing the ability of boys with Duchenne muscular dystrophy age 4-7 years to swallow softgel capsules: Clinical trial experience with edasalonexent.
PMID 34263472 · J Clin Pharm Ther · 2022-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
RESUME-1: a Phase III study of tolperisone in the treatment of painful, acute muscle spasms of the back.
PMID 34192885 · Pain Manag · 2022-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
PMID 34164944 · Arthritis Rheumatol · 2022-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status.
PMID 33993501 · Allergy · 2022-Jan
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial.
PMID 33991341 · Br J Dermatol · 2022-Jan
The study is a randomized controlled trial of a drug (risankizumab) for psoriasis, which is not a malignant neoplasm (oncology). The primary endpoints are response rates (PASI scores), not time-to-event outcomes like OS, PFS, or DFS.
|
H
L
B
|
旧查询独有 |
excludedmodel_adjudicated_excluded |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration.
PMID 33957183 · Ophthalmology · 2022-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors.
PMID 33866774 · Diabetes Metab J · 2022-Jan
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Methodology of the fatigue after stroke educational recovery group randomized controlled trial.
PMID 33724101 · Int J Stroke · 2022-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Randomized trial of azithromycin to eradicate Ureaplasma respiratory colonization in preterm infants: 2-year outcomes.
PMID 33658655 · Pediatr Res · 2022-Jan
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy and Safety of a New Sustained-release Pregabalin Formulation Compared With Immediate-release Pregabalin in Patients With Peripheral Neuropathic Pain: A Randomized Noninferiority Phase 3 Trial.
PMID 35220330 · Clin J Pain · 2022-Feb-28
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).
PMID 34910203 · Mod Rheumatol · 2022-Feb-28
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Different gut microbial communities correlate with efficacy of albendazole-ivermectin against soil-transmitted helminthiases.
PMID 35217670 · Nat Commun · 2022-Feb-25
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Effects of veverimer on serum bicarbonate and physical function in women with chronic kidney disease and metabolic acidosis: a subgroup analysis from a randomised, controlled trial.
PMID 35216581 · BMC Nephrol · 2022-Feb-25
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE).
PMID 35039194 · Vaccine · 2022-Feb-23
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial.
PMID 35191924 · JAMA · 2022-Feb-22
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
PMID 35085503 · Lancet · 2022-Feb-19
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
PMID 35085502 · Lancet · 2022-Feb-19
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension.
PMID 33586606 · Platelets · 2022-Feb-17
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial).
PMID 35169169 · Sci Rep · 2022-Feb-15
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Long-term Efficacy and Safety of Liquid AbobotulinumtoxinA Formulation for Moderate-to-Severe Glabellar Lines: A Phase III, Double-Blind, Randomized, Placebo-Controlled and Open-Label Study.
PMID 34472596 · Aesthet Surg J · 2022-Feb-15
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
The efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate: a single-center, randomized, controlled, open label, phase III study.
PMID 35151280 · BMC Urol · 2022-Feb-12
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
PMID 35023547 · Eur Heart J · 2022-Feb-10
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
PMID 34914868 · N Engl J Med · 2022-Feb-10
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
PMID 34910859 · N Engl J Med · 2022-Feb-10
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients.
PMID 35139816 · J Headache Pain · 2022-Feb-09
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE.
PMID 35135481 · BMC Nephrol · 2022-Feb-08
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
PMID 35133415 · JAMA · 2022-Feb-08
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Referral decisions based on a pre-hospital HEART score in suspected non-ST-elevation acute coronary syndrome: final results of the FamouS Triage study.
PMID 34849660 · Eur Heart J Acute Cardiovasc Care · 2022-Feb-08
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
PMID 34775784 · Circulation · 2022-Feb-08
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials.
PMID 35130836 · J Headache Pain · 2022-Feb-07
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial.
PMID 35093205 · Lancet · 2022-Feb-05
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Quality of Life Following Receipt of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer.
PMID 35226083 · JAMA Netw Open · 2022-Feb-01
属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
|
H
L
B
|
旧查询独有 |
excludedpost_hoc_or_secondary_analysis |
pending
0 Figure · 0 Panel · risk -
|
|
Bimekizumab Self-Injection Devices: Two Multicenter, Randomized, Open-Label Studies on Self-Administration by Patients With Psoriasis.
PMID 35133113 · J Drugs Dermatol · 2022-Feb-01
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
PMID 35029629 · JAMA · 2022-Feb-01
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Efficacy of Treatment With Armodafinil for Cancer-Related Fatigue in Patients With High-grade Glioma: A Phase 3 Randomized Clinical Trial.
PMID 34882169 · JAMA Oncol · 2022-Feb-01
The study is a Phase III randomized trial with a drug intervention in an oncology population, but it does not have a time-to-event efficacy endpoint. The primary outcome is a change in fatigue score, which is not a survival or progression-based endpoint required for inclusion.
|
H
L
B
|
旧查询独有 |
excludedmodel_adjudicated_excluded |
pending
0 Figure · 0 Panel · risk -
|
|
Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults.
PMID 38319179 · NEJM Evid · 2022-Feb
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|
|
Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19.
PMID 38319178 · NEJM Evid · 2022-Feb
未发现恶性肿瘤人群证据。
|
H
L
|
旧查询独有 |
excludednon_oncology |
pending
0 Figure · 0 Panel · risk -
|